Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 5/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.73 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.73 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.73 |
| ▸ | NQO2 | P16083 | 5/20 | 0.73 |
| ▸ | TTR | P02766 | 4/20 | 0.73 |
| ▸ | ABL1 | P00519 | 4/20 | 0.73 |
| ▸ | BCR | P11274 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.73 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | GAA | P10253 | 2/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | GFER | P55789 | 2/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16419899 | 0.90 | PTGS2 (0.68) | CYP1A1PTGS2CYP1B1ALOX5KDM4E | |
| SCHEMBL13793180 | 0.89 | CYP1A1 (0.75) | CYP1A1PTGS2CYP1B1ALOX5KDM4E | |
| SCHEMBL18650797 | 0.88 | RELA (0.56) | CYP1A1PTGS2CYP1B1ALOX5KDM4E | |
| Pterostilbene SCHEMBL3545782 | 0.85 | CYP1A1 (1.00) | CYP1A1PTGS2CYP1B1ALOX5KDM4E | |
| Pterostilbene SCHEMBL20063 | 0.85 | CYP1A1 (1.00) | CYP1A1PTGS2CYP1B1ALOX5KDM4E | |
| Pterostilbene SCHEMBL28222684 | 0.85 | CYP1A1 (1.00) | CYP1A1PTGS2CYP1B1ALOX5KDM4E | |
| Pterostilbene SCHEMBL563218 | 0.85 | CYP1A1 (1.00) | CYP1A1PTGS2CYP1B1ALOX5KDM4E | |
| SCHEMBL9927130 | 0.84 | TUBB4A (0.75) | CYP1A1PTGS2CYP1B1ALOX5KDM4E | |
| SCHEMBL15096130 | 0.83 | CYP1A1 (0.67) | CYP1A1PTGS2CYP1B1ALOX5KDM4E | |
| SCHEMBL14665732 | 0.83 | PTGS2 (0.62) | CYP1A1PTGS2CYP1B1ALOX5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029706-B2 | Methods for treating mucopolysaccharidosis | UNIVERSITY OF MIAMI (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230321002-A1 | ANTICOCCIDIAL COMPOSITION COMPRISING STILBENE-BASED COMPOUND, AND USE THEREOF | CJ CHEILJEDANG CORPORATION (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230270770-A1 | NUTRITIONAL SUPPLEMENTS FOR REPAIRING MUSCLE AND DEFENDING AGAINST DETERIORATION FROM HUMAN AGING | HERNANDEZ VAZQUEZ MOISES (US) | 2023-08-31 | — | — | US | disclosed |
| US-20180221303-A1 | PERITONEAL THERAPEUTIC FLUID | OPTERION HEALTH AG (CH) | 2018-08-09 | — | — | US | disclosed |
| US-20180214387-A1 | AQUEOUS SOLUTION COMPRISING A POLYPHENOL | OPTERION HEALTH AG (CH) | 2018-08-02 | — | — | US | disclosed |
| US-20180214390-A1 | COMBINATION COMPRISING PTEROSTILBENE FOR THE TREATMENT OF CANCER | UNIVERSITAT DE VALÈNCIA - ESTUDI GENERAL (ES) | 2018-08-02 | — | — | US | disclosed |
| US-20180207113-A1 | VIVO INTRACELLULAR REPROGRAMMING COMPOSITION AND METHOD OF MAKING AND USING SAME | GIAMPAPA VINCENT C (US) | 2018-07-26 | — | — | US | disclosed |
| US-10000520-B2 | B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof | ChromaDex Inc. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180000748-A1 | Tincture For Infusing Flavonoids And Methods Of Use | Heart Healthy Spirits, LLC | 2018-01-04 | — | — | US | disclosed |
| US-20170267709-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OFNICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | ChromaDex Inc. (US) | 2017-09-21 | — | — | US | disclosed |
| US-8399712-B2 | Pterostilbene cocrystals | LAURUS LABS PRIVATE LIMITED (IN) | 2013-03-19 | — | — | US | disclosed |
| US-8318807-B2 | Pterostilbene cocrystals | LAURUS LABS PRIVATE LIMITED (IN) | 2012-11-27 | — | — | US | disclosed |
| US-20120178704-A1 | PREVENTION AND TREATMENT OF COLON CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-07-12 | — | — | US | disclosed |
| US-20120035272-A1 | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110189276-A1 | PTEROSTILBENE COCRYSTALS | LAURUS LABS LIMITED (IN) | 2011-08-04 | — | — | US | disclosed |
| US-20110189275-A1 | PTEROSTILBENE COCRYSTALS | LAURUS LABS LIMITED (IN) | 2011-08-04 | — | — | US | disclosed |
| US-20110189277-A1 | PTEROSTILBENE COCRYSTALS | LAURUS LABS LIMITED (IN) | 2011-08-04 | — | — | US | disclosed |
| US-20110189278-A1 | PTEROSTILBENE COCRYSTALS | LAURUS LABS LIMITED (IN) | 2011-08-04 | — | — | US | disclosed |
| US-20110144212-A1 | KEY INTERMEDIATE FOR THE PREPARATION OF STILBENES, SOLID FORMS OF PTEROSTILBENE, AND METHODS FOR MAKING THE SAME | APTUIT LAURUS PRIVATE LIMITED (IN) | 2011-06-16 | — | — | US | disclosed |
| US-20110136751-A1 | Use of Polyphenols in the Treatment of Cancer | GREEN MOLECULAR (ES) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136751-A1 | Use of Polyphenols in the Treatment of Cancer | TP53, PGC, VHL | CYP1A1 505/4885PTGS2 731/4885CYP1B1 1526/4885 |
| US-20110189277-A1 | PTEROSTILBENE COCRYSTALS | CYP3A5, PLPBP, CYP26B1 | CYP1A1 143/4885PTGS2 68/4885CYP1B1 90/4885 |
| US-20110189275-A1 | PTEROSTILBENE COCRYSTALS | CYP3A5, PLPBP, CYP26B1 | CYP1A1 143/4885PTGS2 68/4885CYP1B1 90/4885 |
| US-10000520-B2 | B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof | NAMPT, NAPRT, NNMT | CYP1A1 1882/4885PTGS2 4408/4885CYP1B1 586/4885 |
| US-20120178704-A1 | PREVENTION AND TREATMENT OF COLON CANCER | APC, SI, NFKBIA | CYP1A1 1123/4885PTGS2 28/4885CYP1B1 1133/4885 |
| US-20180207113-A1 | VIVO INTRACELLULAR REPROGRAMMING COMPOSITION AND METHOD OF MAKING AND USING SAME | MTOR, SHMT2, DNMT3A | CYP1A1 1156/4885PTGS2 4173/4885CYP1B1 864/4885 |
| US-20180214387-A1 | AQUEOUS SOLUTION COMPRISING A POLYPHENOL | SORD, AQP1, SI | CYP1A1 631/4885PTGS2 2015/4885CYP1B1 1064/4885 |
| US-20180214390-A1 | COMBINATION COMPRISING PTEROSTILBENE FOR THE TREATMENT OF CANCER | GSTP1, GGT1, GSTA1 | CYP1A1 2456/4885PTGS2 63/4885CYP1B1 1332/4885 |
| US-12029706-B2 | Methods for treating mucopolysaccharidosis | GAA, MAN2B1, IDUA | CYP1A1 3666/4885PTGS2 3036/4885CYP1B1 2534/4885 |
| US-20230270770-A1 | NUTRITIONAL SUPPLEMENTS FOR REPAIRING MUSCLE AND DEFENDING AGAINST DETERIORATION FROM HUMAN AGING | SIRT1, SIRT3, IGFBP1 | CYP1A1 4046/4885PTGS2 1429/4885CYP1B1 3695/4885 |
| US-20120035272-A1 | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration | GPX4, SQLE, PYGB | CYP1A1 747/4885PTGS2 204/4885CYP1B1 737/4885 |
| US-20110189276-A1 | PTEROSTILBENE COCRYSTALS | CYP3A5, PLPBP, CYP26B1 | CYP1A1 143/4885PTGS2 68/4885CYP1B1 90/4885 |
| US-20110189278-A1 | PTEROSTILBENE COCRYSTALS | CYP3A5, PLPBP, CYP26B1 | CYP1A1 143/4885PTGS2 68/4885CYP1B1 90/4885 |
| US-20180000748-A1 | Tincture For Infusing Flavonoids And Methods Of Use | SLC5A6, PNN, NNT | CYP1A1 43/4885PTGS2 2041/4885CYP1B1 6/4885 |
| US-20180221303-A1 | PERITONEAL THERAPEUTIC FLUID | FABP6, ALB, FABP2 | CYP1A1 2351/4885PTGS2 1286/4885CYP1B1 2531/4885 |
| US-20170267709-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OFNICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | NAMPT, NAPRT, NNMT | CYP1A1 1882/4885PTGS2 4408/4885CYP1B1 586/4885 |
| US-20230321002-A1 | ANTICOCCIDIAL COMPOSITION COMPRISING STILBENE-BASED COMPOUND, AND USE THEREOF | VIP, NFATC1, CASP3 | CYP1A1 4700/4885PTGS2 2020/4885CYP1B1 4437/4885 |
| US-20110144212-A1 | KEY INTERMEDIATE FOR THE PREPARATION OF STILBENES, SOLID FORMS OF PTEROSTILBENE, AND METHODS FOR MAKING THE SAME | SIRT5, SQLE, PDHB | CYP1A1 1795/4885PTGS2 638/4885CYP1B1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.